IN8bio/$INAB
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About IN8bio
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
- Ticker
- $INAB
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- New York, United States
- Website
- in8bio.com
IN8bio Metrics
BasicAdvanced
$8.6M
-
-$1.18
-
-
Price and volume
Market cap
$8.6M
52-week high
$2.73
52-week low
$0.80
Average daily volume
40K
Financial strength
Current ratio
5.782
Quick ratio
5.317
Long term debt to equity
0.134
Total debt to equity
0.194
Profitability
EBITDA (TTM)
-18.602
Management effectiveness
Return on assets (TTM)
-70.34%
Return on equity (TTM)
-141.83%
Valuation
Price to book
0.61
Price to tangible book (TTM)
0.61
Price to free cash flow (TTM)
-0.952
Free cash flow yield (TTM)
-105.05%
Free cash flow per share (TTM)
-0.916
Growth
Earnings per share change (TTM)
-81.37%
3-year earnings per share growth (CAGR)
-67.06%
IN8bio Financial Performance
Revenues and expenses
IN8bio Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.